Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4/A

LIGAND PH Form 4/A June 04, 2013	ARMACEUT	ICALS ING	C									
FORM	4								OMB AI	PROVAL		
Washington, D.C. 20549								OMB Number:	3235-0287			
if no long subject to	Section 16. SECURITIES								burden hou	Estimated average burden hours per		
Form 5 obligation may conti	Form 5 obligations may continue. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type R	esponses)											
FOEHR MATTHEW W Syn			Symbol LIGANI	2. Issuer Name and Ticker or Trading Symbol LIGAND PHARMACEUTICALS NC [LGND]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)(First)(Middle)3. Date of (Month/Da11119 NORTH TORREY PINES04/18/20ROAD, SUITE 20004/18/20								below)	ve title Other (specify below) EVP and COO			
				ndment, Date Original th/Day/Year))11				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person 				
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)		Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired Transaction(A) or Disposed of Code (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price				6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of			
Common Stock	04/18/2011			A	16,667 (1)	A	\$ 0	16,667	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	ivative Conversion (Month/Day/Year urity or Exercise		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed or (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour Underlying Securit (Instr. 3 and 4)					
				Code V	(A) (D	Date Exercisable	Expiration Date	Title	Amo or Num of Sh				
Non-Qualified Stock Option (right to buy)	\$ 9.97	04/18/2011		A	51,546 (2)	<u>(3)</u>	04/18/2021	Common Stock	51,5				
Reporting Owners													
Reporting Owner Name / Address		e / Address	R	elationship	DS								
]	Director 10% Own	er Office	r	Other							
FOEHR MATTHEW W 11119 NORTH TORREY PINES ROAD SUITE 200 LA JOLLA, CA 92037			EVP and COO										
Signature	es												
By: John P. Sh Foehr	arp For: Ma	atthew W.	06/04/2013										

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4/A

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

(1) Amended to correct the number of restricted stock units issued.

**Signature of Reporting Person

(2) Amended to correct the number of options issued from 51,547 to 51,546.

(3) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Optioned Shares per month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.